^
    Back
    Association details:
    Biomarker:ANK2 overexpression
    Cancer:Lung Adenocarcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Pulm Med
    Title:

    ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

    Published date:
    12/20/2022
    Excerpt:
    Our study aimed to identify potential biomarkers predicting ICIs efficacy in LUAD….a higher level of ANK2 expression was associated with longer overall survival (HR 0.69, 95% CI 0.52–0.92; P = 0.012) in TCGA LUAD cohort.
    DOI:
    https://doi.org/10.1186/s12890-022-02279-2